In focus · trending topic

PI3K dual delta gamma inhibitor

4 stories · following the connections

Rhizen Pharmaceuticals S.A. announces clinical data presentations for Tenalisib (RP6530) in R/R T-cell lymphoma at the upcoming 10th Annual T-Cell Lymphoma Forum in La Jolla, CA, USA

By Nasdaq OMXJan 29, 2018, 12:00 PM UTC

Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of peripheral T-cell lymphoma (PTCL)

By Nasdaq OMXDec 22, 2017, 1:00 PM UTC

Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for RP6530 (tenalisib), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL)

By Nasdaq OMXDec 9, 2017, 1:00 PM UTC

Rhizen Pharmaceuticals S.A. announces clinical and preclinical data presentations at the upcoming 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, GA, USA

By Nasdaq OMXDec 5, 2017, 12:00 PM UTC